Speculative Bullish Options Positioning in Bristol-Myers Squibb (BMY) -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Bristol-Myers Squibb (BMY) Announces Presentations at IASLC
September 27, 2017 5:07 PM EDTBristol-Myers Squibb Company (NYSE: BMY) today announced the presentation of 28 abstracts for Opdivo (nivolumab), alone and in combination with Yervoy (ipilimumab), targeted therapy or chemotherapy, at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan, from October 15-18. Data from company-sponsored studies, clinical collaborations and... More
Bristol-Myers Squibb (BMY) Investor Meeting Feedback Comments From Jefferies
September 27, 2017 7:54 AM EDTJefferies maintains Buy on Bristol-Myers Squibb Co. (NYSE: BMY) price target of $72.00.
Analyst Jeff Holford says business development remains a top priority at the company noting the firm remains agnostic on deal size and listed three criteria when evaluating... More
